ClinicalTrials.gg
RecruitingNCT07602296LewyLIGHTUpdated Oct 27, 2026

Evaluating How Red-light Therapy Applied to the Head Affects Symptoms, Daily Life, and Brain Activity in People With Dementia With Lewy Bodies

An interventional study of LUCIOLE CAP and LUCIOLE CAP (sham version) in Photobiomodulation and Dementia With Lewy Bodies, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 27, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Lewy Body Disease with a site in France — 9 open to participants now, 9 under way, 1 of them phase 3. Lewy Body Disease · France.

Planned enrollment
18th of 22
40 · median 130
Started
2026
with 1 other
No phase
14 of 30
4 open now
Registered
30th of 30
by date
Lead sponsor
6 of 30
University Hospital, Strasbourg, France

Among the 30 studies in Lewy Body Disease with a site in France, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 30th registered.

Lewy Body Disease

240 studies on the registry are indexed under Lewy Body Disease; 89 are open to participants now.

Browse Lewy Body Disease studies →

Open to participants now

9 of the 30 studies in Lewy Body Disease with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 64 Lewy Body Disease studies recruiting now, 42 (66%) set no upper age limit and none (0%) stop at 75 or younger; 10 take children under 18; 31 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Lewy Body Disease with a site in France, or all of them as a file.
02

Study summary

Dementia with Lewy bodies (DLB) is a neurodegenerative disease diagnosed primarily based on the presence of cognitive decline, which may include difficulties with memory, attention, and more. Additionally, at least two of the following symptoms are needed for a probable diagnosis of DLB, and at least one for a possible DLB diagnosis (McKeith et al. 2017 and 2020):

  • Fluctuations in cognition, attention, and/or alertness
  • Visual hallucinations
  • Spontaneous parkinsonism
  • REM sleep behavior disorder

Patients with DLB can experience cognitive deficits that can fluctuate and can vary for each patient. These may include deficits in memory, executive functions (planning and organizing), attention, visual processing, and language.

This study aims to evaluate the effect of red-light therapy, delivered using a helmet that contains small LED lights, in patients with DLB.

Participants' cognitive functions, clinical symptoms, quality of life and functional cerebral connectivity will be evaluated before starting therapy and again after three and six months of twice daily therapy use. As DLB also indirectly affects caregivers, the caregiver's quality of life and burden will also be evaluated before and at three and six months of therapy use by the participant.

The study's inclusion period is 24 months and the duration of participation for each patient is 8 months (+/-10 days) maximum.

Read the detailed description

Dementia with Lewy bodies (DLB) is the second most frequent neurodegenerative disease after Alzheimer's disease and represents 15 to 20% of dementia cases (Ballard et al. 2001; Zaccai et al. 2005; Aarsland et al. 2008). DLB is diagnosed primarily based on the presence of cognitive decline, which is most often perceived as difficulties relating to attention, visuospatial capacities and executive functions like planning, decision making and more.

Additionally, at least two of the following core clinical symptoms are needed for a probable diagnosis of DLB, and at least one for a possible DLB diagnosis (McKeith et al. 2017 and 2020):

  • Fluctuations in cognition, attention, and/or alertness
  • Visual hallucinations
  • Spontaneous parkinsonism
  • REM sleep behavior disorder

Suggestive symptoms may support the diagnosis of probable DLB when at least one core clinical symptom is present together with one of the following features, or possible DLB when one or more of the following features are present in the absence of any core clinical feature (McKeith et al. 2017 and 2020):

  • Severe sensitivity to neuroleptics
  • Postural instability
  • Recurrent falls
  • Syncope or transient episodes of responsiveness
  • Severe autonomic dysfunction: constipation, urinary incontinence, etc.
  • Hallucinations in other sensory modalities (ex. auditory)
  • Delusions
  • Apathy, anxiety, depression
  • Reduced dopamine transporter uptake in basal ganglia on DAT scan
  • Abnormal cardiac I-MIBG scintigraphy (reduced myocardial MIBG uptake)
  • MRI or CT: relative preservation of medial temporal lobe structures
  • SPECT or PET: reduced tracer uptake with occipital hypometabolism
  • EEG: prominent posterior slow wave activity with periodic fluctuations in the pre-alpha/theta range

There is currently no treatment for DLB (Mueller et al. 2017). The effectiveness of available symptomatic treatments is also limited and sometimes accompanied by severe side effects (Boot et al. 2013; Boot, 2015). There is therefore an urgent need to develop therapeutic solutions adapted to DLB, aiming at neuroprotection and/or improvement of the quality of life of patients through better management of clinical symptoms. We are particularly interested in non-invasive and non-pharmacological approaches, with the aim of identifying methods without side effects and can easily be used by patients daily.

In this context, a new approach is the subject of growing interest within the medical and scientific communities, as well as the general public. Known as photobiomodulation (PBM), this technique involves applying red to infrared light (λ=600-1000nm) on biological tissues.

This study aims to evaluate the effect of transcranial PBM in patients with DLB.

Participants' cognitive functions, clinical symptoms, quality of life and cerebral connectivity will be evaluated before starting therapy and again after three and six months of twice daily therapy use. As DLB also indirectly affects caregivers, the caregiver's quality of life and burden will also be evaluated before and at three and six months of therapy use by the participant.

03

Conditions studied

  • Photobiomodulation
  • Dementia With Lewy Bodies

Browse trials for

Keywords

  • Photobiomodulation (PBM)
  • Dementia with Lewy bodies (DLB)
  • Cognitive functions
  • Clinical symptoms
  • Quality of life
  • Cerebral connectivity
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman, 50 years or older
  • Probable DLB diagnosed according to the criteria of McKeith et al., 2017, or the criteria of McKeith et al., 2020 for prodromal DLB
  • Score on the (MMSE; Folstein et al., 1983) ≥ 18/30 at their last medical visit
  • Good mastery of the French language
  • Accompanied by a caregiver or a person able to provide information about them (interview, by telephone).
  • Able to understand the objectives and risks associated with the research and to give , dated and signed
  • Covered by a social health insurance plan
  • Having a head circumference between 54 and 62 cm.

Exclusion criteria

Exclusion criteria:

  • Not able to understand the objectives and risks related to research and to give
  • Presence of another neurological disorder, including but not limited to brain tumors, stroke with potential cognitive impairment, or diagnosis of another progressive neurological disease (e.g., Alzheimer's disease, Parkinson's disease, etc.), and as determined by the investigator
  • Having an score \< 18 at the screening visit
  • Unable to undergo a brain MRI due to medical reasons
  • Participants whose follow-up would likely be disrupted during the study period (e.g., due to planned relocation or other reasons)
  • Insufficient proficiency of the French language
  • Participants experiencing an emergency of life-threatening situation
  • Alone, without a caregiver present
  • Participants presenting with a head/scalp injury
  • Participants with a silicone allergy
  • Participants with cranial/skull shape abnormalities
  • Participants with a head circumference outside the range of 54-62 cm
  • Participants requiring life support, continuous monitoring, and/or implanted medical devices (AIMD)
  • Participants taking the antiepileptic Keppra (Levetiracetam)
  • Participants whose anticholinesterase treatments have been changed within the past 2 months
  • Participants whose antipsychotic treatments have been changed within the last 15 days
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active

    The participants assigned to the active group will each receive an active LUCIOLE cap to be used at home twice daily for six months with the assistance of their caregiver. A minimum interval of four hours is required between the two daily sessions. Each session lasts for 32 minutes (including 24 minutes of active near-infrared red light and 8 minutes of cooling periods spaced throughout the session). The cap automatically turns off at the end of each session. The caregiver assists the participant in placing the cap on correctly, verifies that the cap works properly, and starts the session. All participants in the active group will undergo neuropsychological evaluations, clinical and neurological examinations, MRIs, and blood tests and at months 0, 3 and 6 of the study. Participants will also be evaluated at month 7, one month after the end of the photobiomodulation sessions, during which the same clinical, neurological and neuropsychological evaluations will be administered.

    Device: LUCIOLE CAP

  • Sham comparator
    Sham

    Participants in the sham group will follow the same PBM schedule as the participants in the active group: twice daily sessions of 32 minutes for six months (see active group description for more information) except they will use the sham LUCIOLE cap. The sham cap mimics the appearance, heating and operation of the active cap but does not deliver PBM. The only difference between the two versions is in the internal electronics and firmware modifications. The two versions can only be differentiated by their serial numbers. All participants in the study, as well as the research team, do not know which caps are active and which are sham. As in the active group, participants in the sham group will undergo neuropsychological evaluations, clinical and neurological examinations, MRIs, and blood tests and at months 0, 3 and 6 of the study. Participants will also be seen at month 7, one month after the end of the PBM sessions, for clinical, neurological and neuropsychological evaluations.

    Device: LUCIOLE CAP (sham version)

Interventions

  • DeviceLUCIOLE CAP

    The LUCIOLE Cap is a medical device (without CE mark) designed for transcranial photobiomodulation (PBM). The cap was developed specifically for this purpose by the CLINATEC Endowment Fund (FDC), and it has not been used in any clinical investigation before. The LUCIOLE Cap will be used for the first time in this study with patients diagnosed with Dementia with Lewy bodies. The LUCIOLE cap is a non-invasive device that delivers PBM to the brain by shining light through the skin and bone. The LEDs emit near-infrared-light at a wavelength of 810 nm, with an illumination power of up to 8W (\~40mW/cm²). For safety, the cap must only be used in the room chosen by the study investigator during the first home visit. It must be used in a dry environment, away from sources of water or moisture, avoiding direct sunlight, and at a room temperature between 5°C and 27.5°C.

  • DeviceLUCIOLE CAP (sham version)

    The CLINATEC Endowment Fund (FDC) designed this sham cap exclusively for scientific studies. It is built specifically to provide an accurate comparison against the active cap. This precise control allows investigators to clearly evaluate whether the active LUCIOLE cap delivers true, measurable benefits. The sham cap mimics the active LUCIOLE cap's operational characteristics and heat output without delivering actual PBM. The devices look identical and are distinguishable only by their serial numbers. This internal difference in electronics and firmware guarantees that both clinical investigators and participants remain blinded to the treatment allocation. For safety, the cap must only be used in the room chosen by the study investigator during the first home visit. It must be used in a dry environment, away from sources of water or moisture, avoiding direct sunlight, and at a room temperature between 5°C and 27.5°C.

06

What researchers measure

Primary outcomes

  1. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    (Randolph et al., 1998)

    Time frame: Measurements done right before start of PBM (at month 0 (M0)), after 3 months of PBM (M3), after six months of PBM (M6), and one month after end of PBM (M7)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2029, 32 months after the start.

Of 59 non-industry interventional studies with no phase under Lewy Body Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 63 studies reached it within 35 months; a quarter within 26 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jun 2026 → Sep 2026, primary completion Dec 2028 → May 2029 and completion Mar 2029 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Sep 16, 2026was Jun 2026
Primary completionEst.
May 2029was Dec 2028
CompletionEst.
May 2029was Mar 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
Hôpitaux Universitaires de Strasbourg is now Recruiting
Oct 27, 2026
Start date
Jun 2026→Sep 16, 2026 (actual)
Oct 27, 2026
Primary completion
Dec 2028→May 2029
Oct 27, 2026
Study completion
Mar 2029→May 2029
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    Hôpitaux Universitaires de Strasbourg is now Recruiting
    Start date Jun 2026→Sep 16, 2026 (now actual)
    Primary completion Dec 2028→May 2029
    Study completion Mar 2029→May 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07602296
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Sep 16, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Frédéric Professor BLANC, Professor
Contact
frederic.blanc@chru-strasbourg.fr
+33 3 88 11 56 24

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion